BioNTech SE
BNTX
$99.47
$2.012.06%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.44% | -24.11% | -85.13% | -63.58% | -72.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.44% | -24.11% | -85.13% | -63.58% | -72.06% |
| Cost of Revenue | 11.68% | -63.70% | -37.68% | 2.84% | -76.78% |
| Gross Profit | 46.78% | 1,319.37% | -88.99% | -66.55% | -70.75% |
| SG&A Expenses | -0.97% | 31.80% | 8.25% | -0.98% | 7.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,070.59% | 1,599.24% | 84.50% | 100.96% | -88.31% |
| Total Operating Expenses | 46.66% | 64.15% | 40.26% | 50.51% | -40.21% |
| Operating Income | -59.71% | -94.41% | -165.42% | -82.90% | -97.08% |
| Income Before Tax | -29.51% | -93.30% | -147.46% | -77.97% | -89.95% |
| Income Tax Expenses | -159.58% | 100.89% | -108.23% | -75.80% | -89.05% |
| Earnings from Continuing Operations | 24.59% | -319.53% | -163.51% | -78.83% | -90.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.59% | -319.53% | -163.51% | -78.83% | -90.28% |
| EBIT | -59.71% | -94.41% | -165.42% | -82.90% | -97.08% |
| EBITDA | -29.61% | -97.18% | -158.09% | -82.01% | -94.87% |
| EPS Basic | 23.63% | -320.57% | -164.06% | -78.54% | -90.26% |
| Normalized Basic EPS | -13.95% | -89.91% | -144.33% | -76.71% | -89.69% |
| EPS Diluted | 23.96% | -320.57% | -164.69% | -78.42% | -89.79% |
| Normalized Diluted EPS | -13.71% | -89.91% | -144.77% | -76.54% | -89.19% |
| Average Basic Shares Outstanding | 0.79% | -0.25% | -0.85% | -1.31% | -0.22% |
| Average Diluted Shares Outstanding | 0.51% | -0.25% | -1.81% | -2.06% | -4.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
